Actelion Ltd. (OTCMKTS:ALIOF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Actelion Limited is an independent, profitable, biopharmaceutical company discovering, developing and marketing drugs for high unmet medical needs. “

Actelion Company Profile

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Receive News & Ratings for Actelion Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion Ltd. and related companies with's FREE daily email newsletter.